| Abstract: |
The immune system plays a role in recognition and elimination of tumors through immune surveillance. Tumors can evade surveillance by upregulating inhibitory signals or "checkpoints" to suppress T cell activation. The development of checkpoint inhibitors, antibodies directed to cytotoxic T lymphocyte-associated protein 4 (CLTA-4) and programmed cell death-1 (PD-1/PD-L1), has led to promising durable responses in some solid and hematologic malignancies. This chapter reviews the development and preclinical rationale of checkpoint inhibition and highlights the evolving clinical utility of agents targeting these molecules. © 2018 John Wiley & Sons, Inc. All rights reserved. |
